EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study

Fabrizio Nelli iD, Agnese Fabbri iD, Antonella Virtuoso, Diana Giannarelli iD, Julio Rodrigo Giron Berrios iD, Eleonora Marrucci, Cristina Fiore, Marta Schirripa, Carlo Signorelli iD, Mario Giovanni Chilelli, Francesca Primi, Gloria Pessina iD und 3 weitere

Current Oncology · 2023

DOI: 10.3390/curroncol30050386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Fabrizio Nelli und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy. Hauptthemen laut MEDLINE: COVID-19, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

(1)

Background

The clinical implications of COVID-19 outbreaks following SARS-CoV-2 vaccination in immunocompromised recipients are a worldwide concern. Cancer patients on active treatment remain at an increased risk of developing breakthrough infections because of waning immunity and the emergence of SARS-CoV-2 variants. There is a paucity of data on the effects of COVID-19 outbreaks on long-term survival outcomes in this population. (2)

Methods

We enrolled 230 cancer patients who were on active treatment for advanced disease and had received booster dosing of an mRNA-BNT162b2 vaccine as part of the Vax-On-Third trial between September 2021 and October 2021. Four weeks after the third immunization, IgG antibodies against the spike receptor domain of SARS-CoV-2 were tested in all patients. We prospectively evaluated the incidence of breakthrough infections and disease outcomes. The coprimary endpoints were the effects of antibody titers on the development of breakthrough infections and the impact of COVID-19 outbreaks on cancer treatment failure. (3)

Results

At a median follow-up of 16.3 months (95% CI 14.5–17.0), 85 (37%) patients developed SARS-CoV-2 infection. Hospitalization was required in 11 patients (12.9%) and only 2 (2.3%) deaths related to COVID-19 outbreaks were observed. Median antibody titers were significantly lower in breakthrough cases than in non-cases (291 BAU/mL (95% CI 210–505) vs. 2798 BAU/mL (95% CI 2323–3613), p < 0.001). A serological titer cut-off below 803 BAU/mL was predictive of breakthrough infection. In multivariate testing, antibody titers and cytotoxic chemotherapy were independently associated with an increased risk of outbreaks. Time-to-treatment failure after booster dosing was significantly shorter in patients who contracted SARS-CoV-2 infection (3.1 months (95% CI 2.3–3.6) vs. 16.2 months (95% CI 14.3–17.0), p < 0.001) and had an antibody level below the cut-off (3.6 months (95% CI 3.0–4.5) vs. 14.6 months (95% CI 11.9–16.3), p < 0.001). A multivariate Cox regression model confirmed that both covariates independently had a worsening effect on time-to-treatment failure. (4)

Conclusions

These data support the role of vaccine boosters in preventing the incidence and severity of COVID-19 outbreaks. Enhanced humoral immunity after the third vaccination significantly correlates with protection against breakthrough infections. Strategies aimed at restraining SARS-CoV-2 transmission in advanced cancer patients undergoing active treatment should be prioritized to mitigate the impact on disease outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsHumansCOVID-19 VaccinesAntibody FormationSARS-CoV-2BNT162 VaccineBreakthrough InfectionsButylamines

Stichwörter der Autor:innen

COVID-19SARS-CoV-2active treatmentadvanced diseasebreakthrough infectionsolid tumorsthird dosetozinameranvaccination

Substanzen

COVID-19 VaccinesBNT162 VaccinedibutadiamineButylamines

Autor:innen und Institutionen

  • Department of Oncology and Hematology, Medical Oncology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy.
  • Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy.
  • Department of Oncology and Hematology, Molecular Biology and Covid Diagnostics, Central Hospital of Belcolle, 01100 Viterbo, Italy.
  • Department of Oncology and Hematology, Microbiology and Virology Unit, Central Hospital of Belcolle, 01100 Viterbo, Italy.

ORCID-Profile: Fabrizio Nelli, Agnese Fabbri, Diana Giannarelli, Julio Rodrigo Giron Berrios, Carlo Signorelli, Gloria Pessina, Federica Natoni

Zitieren

APA

Nelli, F., Fabbri, A., Virtuoso, A., Giannarelli, D., Giron Berrios, J. R., Marrucci, E., Fiore, C., Schirripa, M., Signorelli, C., Chilelli, M. G., Primi, F., Pessina, G., Natoni, F., Silvestri, M. A., & Ruggeri, E. M. (2023). Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study. Current Oncology. https://doi.org/10.3390/curroncol30050386

Vancouver

Nelli F, Fabbri A, Virtuoso A, Giannarelli D, Giron Berrios JR, Marrucci E, et al. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study. Current Oncology. 2023. doi:10.3390/curroncol30050386

BibTeX
@article{Nelli2023,
  author = {Nelli, Fabrizio and Fabbri, Agnese and Virtuoso, Antonella and Giannarelli, Diana and Giron Berrios, Julio Rodrigo and Marrucci, Eleonora and Fiore, Cristina and Schirripa, Marta and Signorelli, Carlo and Chilelli, Mario Giovanni and Primi, Francesca and Pessina, Gloria and Natoni, Federica and Silvestri, Maria Assunta and Ruggeri, Enzo Maria},
  title = {Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30050386}
}
Kostenlos starten →